Varras M N, Koffa M, Koumantakis E, Ergazaki M, Protopapa E, Michalas S, Spandidos D A
Laboratory of Clinical Virology, Medical School, University of Crete, Heraklion, Greece.
Oncology. 1996 Nov-Dec;53(6):505-10. doi: 10.1159/000227627.
The purpose of this study was to assess the extent of involvement of the ras oncogene activation by point mutations in endometrial carcinoma in the Greek population. The PCR technique was employed, followed by RFLP analysis to identify the point mutations in codon 12 of the K-ras, H-ras and N-ras genes. K-ras gene point mutations were detected in 8 of the 55 cases (15%) of primary endometrial carcinoma, H-ras in 4 (7.3%), while no mutations were found for the N-ras gene. No correlation was found between the presence of ras gene mutations and the clinicopathological parameters, or patient survival. The only association found was between H-ras mutations and the FIGO stage of the tumor (Fisher's exact test, p = 0.011). These results indicate a possible role of ras gene activation in a small subset of endometrial carcinomas.
